Clinical Trials Browser

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

85 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

55 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06904170 2026-02-03

ALICE

Phase 2/3 Recruiting

196 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

39 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

72 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Phase 2 Recruiting

32 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07081633 2025-12-30

TREMENDOUS-2

Phase 2 Recruiting

114 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06880523 2025-12-18

SLIDE-HCC

Phase 2 Recruiting

140 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05733598 2025-12-15

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Phase 2 Recruiting

21 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06698250 2025-11-06

ZENOBIA

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

Phase 2 Recruiting

45 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Phase 1 Recruiting

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

660 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06999707 2025-06-05

Photon-STRIDE

Phase 2 Recruiting

45 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06911255 2025-05-14

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Phase 1/2 Recruiting

24 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06045975 2025-04-02

DUMELEP

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06710223 2025-02-11

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Phase 1 Recruiting

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05557838 2025-02-07

TREMENDOUS

Phase 3 Recruiting

210 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05440864 2024-10-10

(NEOTOMA)

Phase 2 Recruiting

28 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05844046 2024-07-16

MONTBLANC

Phase 2 Recruiting

83 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Phase 2 Recruiting

90 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04988945 2023-09-06

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Phase 2 Recruiting

33 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05809869 2023-04-12

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03482102 2022-09-08

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Phase 2 Recruiting

70 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular